Precision Biologics to present data on new antibody-drug conjugate PB-223 ADC at AACR, Chicago, IL, April 25 – 30, 2025
Precision Biologics, Inc. will present new data on a newly developed Antibody-Drug Conjugate PB-223 ADC...
25Apr
18Apr
Dr. Philip M Arlen to present at Festival of Biologics USA, San Diego, CA, April 23 – 24, 2025
Precision Biologics, Inc. CEO Philip M Arlen, MD will give the Keynote speech, and also...
18Apr
Precision Biologics highlighted in GEN article, April 2025 issue
An article titled “Cancer Vaccines-Improving Their Aim” in the current April 2025 issue of trade...
07Mar
Precision Biologics, Inc. to present at Antibody Therapeutics Xchange, April 15th, 2025, Philadelphia, PA
Precision Biologics announces that our Chief Scientific Officer, Kwong "Al" Tsang, will deliver a talk...
14Feb
Precision Biologics, Inc. to present at AACR IO 2025, February 24, 2025, Los Angeles, CA
Precision Biologics announces that our Director of Research & Development, Massimo Fantini, PhD, will deliver...
14Feb
Dr. Philip M Arlen to present at DDIP 2025, March 3-4, 2025, San Diego, CA
Precision Biologics, Inc. CEO, Philip M Arlen, MD, will participate on an interactive panel (Day...
06Nov
Precision Biologics to Announce Development of New Monoclonal Antibody (mAb) PB-223 at SITC, Houston, TX, November 7-8, 2024
Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope...
04Nov
Precision Biologics, Inc. to present recent data on the development of new monoclonal antibody (mAb) PB-223 at SITC 2024
Precision Biologics, Inc. will present novel data about affinity maturation and characterization of a novel...
22Oct
Read more...
23Sep
Precision Biologics, Inc. announces new US Patent filing on optimized antibody PB-233
Precision Biologics announces the filing of a new patent for our second asset, PB-233. This...